MET gene amplification ranging from frequencies of 1-20% has been documented in a variety of human cancers, including liver metastases from colon carcinoma [23], non-small cell lung carcinomas with acquired resistance to EGFR inhibitors [24] and gastric cancers [16, 17]. Here, MET is linked to colon carcinoma.